Janux Therapeutics Inc (JANX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $16.52 (-2.02%), Market cap $0.85B, 52-week low–high $12.18 ~ $34.74.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squam
Financial statements, price targets, institutional (13F) holdings and related news for Janux Therapeutics Inc are updated in real time on BlackAll Trade.
Janux Therapeutics Inc trades at $16.52 (-2.02%). Real-time quotes and charts are available on BlackAll Trade.
Janux Therapeutics Inc has a market cap of about $0.85B.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive